The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Judite Blanc, PhD: VR on Maternal Stress, Sleep Reduction in Women of Color
During SLEEP 2024, Judite Blanc, PhD, discussed her team’s ongoing study assessing whether an education VR program improves maternal stress and sleep among women of color.
Josiane Broussard, PhD: Meal Timings Impact on Sleep
At SLEEP 2024, Broussard told HCPLive about how eating time restriction can serve as another as another dietary tool for people who are unsuccessful with other strategies.
Josiane Broussard, PhD: Meal Timings Effect on Cardiometabolic Health, Sleep
Broussard discussed the importance of eating during the day at SLEEP 2024.
Allison Brager, PhD: Exercise’s Impact on Cardiovascular Health, Circadian Clock
In an interview at SLEEP 2024, Brager talked about the benefits of exercise on cardiovascular health and sleep.
Sairam Parthasarathy, MD: Researching Sleep Disturbances’ Impact on Immunity
Parthasarathy discussed next steps for research on the relationship between sleep disturbances and immunity in an interview with HCPLive at SLEEP 2024.
Sairam Parthasarathy, MD: Sleep Issues Affect COVID-19, Vary by Sex
Parthasarathy told HCPLive women have a weaker immune response to COVID-19 than men.
Sairam Parthasarathy, MD: How Sleep Disturbances Impact Immune Function
In an interview with HCPLive, Parthasarathy discussed the relationship between sleep disturbances and immune function.
Lourdes DelRosso, MD, PhD: Goals, Insights from the “Count on Sleep” OSA Project
In an interview with HCPLive, DelRosso spoke about the 1-year plans of the "Count on Sleep" OSA project.
Amee Revana, DO, FAASM: Pitolisant Reduces Sleepiness in Prader-Willi Syndrome
At SLEEP 2024, Revana told HCPLive her thoughts on the potential of pitolisant to address excessive daytime sleepiness in Prader-Willi syndrome compared to treating narcolepsy.
Bruce Sands, MD: Phase 3 Treat-Through Data for Mirikizumab in Crohn’s Disease
Sands reviews key findings from the phase 3 VIVID-1 study of mirikizumab in Crohn’s disease presented at DDW.
Postmenopausal Women with Vasomotor Symptoms Have Frequent Sleep Issues
Analysis of the OASIS trial shows, on average, women post-menopause with vasomotor symptoms experience at least moderate rates of sleep disturbance.
Pharyngeal Opening Pressure More Common in Black Patients with OSA
A cohort analysis suggests upper airway collapsibility prevalence may correlate closely to race in patients with OSA.
Patients More Likely to Adhere to Fixed CPAP Versus Automatic Titration Option
New study data show patients with OSA may use a fixed CPAP device for a longer daily duration than those with an automatic option.
No Link Found Between Nightmare Severity and Next-Day Suicidal Ideation Severity
Presented at SLEEP 2024 as a late-breaker, a study found a positive relationship exists between suicide severity on any day and next-day suicide severity.
Sleep Disorders not Linked to Worse QoL in Veterans with PTSD
New data presented at SLEEP 2024 show sleep disorders including insomnia are only linked to worse quality of life when veterans do not also have PTSD.
Medicinal Cannabis Shows Promise for Managing Sleep in Children with ASD
A study presented at SLEEP 2024 found medicinal cannabis shows promise for improving sleep onset latency, quality, and duration in children with ASD.
Tirzepatide Significantly Reduces Weight in Patients with OSA
New analysis from SURMOUNT-1 support the use of GLP-1/GIP agonist tirzepatide to reduce weight in patients with OSA and obesity/overweight.
Melatonin Increased Hospitalized Patients' Sleep Quality by 32%
A study presented at SLEEP 2024 found melatonin increased sleep latency and overall sleep quality and decreased awakenings.
OSA Mandibular Advancement Devices Optimized by Jaw Movement Monitoring
A late-breaking abstract from SLEEP 2024 shows the effect of mandibular devices on respiratory effort, and its overall impact on OSA.
Novel Mouthguard Device Significantly Reduces Nightly Sleep Apnea Events
An alternative device to CPAP shows clinical benefit and long-term patient adherence in new SLEEP 2024 trial data.
Persistent Insomnia Symptoms Linked to a Greater Depression Risk
A study presented at SLEEP 2024 found persistent or progressive insomnia symptoms are linked to a greater depression risk than subthreshold cases with gradual improvement.
Seltorexant Meets Primary, Secondary Endpoints in Phase 3 Trial for MDD, Insomnia
Announced on May 29, 2024, data from the MDD3001 trial indicate use of seltorexant was associated with meaningful improvements in depressive symptoms and sleep disturbances.
Why Are Adult ADHD Cases Climbing?
Julie Thomas, MS, DMSc, PA-C, discusses why ADHD cases may go undetected into adulthood, and the methods to treat such patients.
Zodasiran Reduces Triglycerides, ANGPTL3 in Mixed Hyperlipidemia in ARCHES-2 Trial
A phase 2 trial suggests zodasiran significantly reduces triglycerides in patients with mixed hyperlipidemia, showing dose-dependent improvements in lipid profiles.
How Psoriatic Arthritis Presentation, Treatment Has Evolved
Benjamin J. Smith, DMSc, PA-C, discusses the importance of defining comorbidities in diagnosing PsA, as well as prescribing biologics.
Alan Bonder, MD: Phase 2 Data for Combination Obeticholic Acid, Bezafibrate in PBC
Bonder explains key therapeutic targets in primary biliary cholangitis and why combination obeticholic acid and bezafibrate may be a promising option.
Optimizing Diabetes Therapies with New Classifications
Ji Hyun “CJ” Chun, MPAS, PA-C, BC-ADM, explains how the adoption of 5 new diabetes subtypes may foster precision care.
Anthony Lembo, MD: Exploring Probiotics for IBS Treatment
Lembo describes the potential of a multi-species synbiotic for the treatment of IBS based on findings from an exploratory study he presented at DDW.
Iptacopan Reduces Proteinuria, Demonstrates Benefit in C3 Glomerulopathy
In the APPEAR-C3G trial, iptacopan reduced proteinuria by 35.1% in patients with C3 glomerulopathy, with Novartis planning regulatory submissions for C3G before the end of 2024.
Vlado Perkovic, MBBS, PhD: Semaglutide's Role in CKD Based on FLOW Results
Vlado Perkovic, MBBS, PhD, discusses the results of the FLOW trial and their implications for clinical practice at ERA 24.